

Annual meeting of the Swedish AML Group 2020

Venue: Sigtuna stiftelsen, near Stockholm Arlanda airport

Dates: January 23-24, 2020

Thursday, January 23: Preclinical and translational research

**10:00-12:00 Swedish Registry Group meeting; open for all participants
(Chair Gunnar Juliusson, Lund)**

10:00-10:30 Secondary and therapy-related AML (Christer Nilsson, Stockholm)

10:30-11:00 Swedish acute leukemia registry – an update (Gunnar Juliusson, Lund)

11:00-11:30 Studies in pipeline based from the registry (Gunnar Juliusson, everyone)

11:30-12:00 Discussion (Gunnar Juliusson, everyone)

12:00-13:00 Lunch

**13:00-15:00 SCIENTIFIC PROGRAM I: Drug screening and novel targets
(Chair Sören Lehmann, Uppsala)**

13:00-13:40 Keynote lecture: High-throughput drug screening (Olli Kallioniemi, Stockholm)

13:40-14:00 Oral: Novel drug targets (Julian Walfridsson, Stockholm)

14:00-14:40 Keynote: Chromatin and epigenetic aberrations in AML (Sören Lehmann, Uppsala)

14:40-15:00 Oral: Novel biomarkers (Anna Eriksson, Uppsala)

15:00-15:30 Coffee

15:30-17:30 SCIENTIFIC PROGRAM II: Genetics and stem cells (Chair Marcus Järås, Lund)

15:30-16:10 Keynote: CRISPR screens to identify therapeutic opportunities in AML (Marcus Järås, Lund)

16:10-16:30 Oral: Development and treatment of AML (Andreas Lennartsson, Stockholm)

16:30-17:10 Keynote: Personalized analysis of measurable residual disease (Linda Fogelstrand, Göteborg)

17:10-17:30 Oral: Targeting mitochondrial transcription in AML (Laleh Arabanian, Göteborg)

19:00 Dinner

Friday, January 24: Clinical and study group meeting

08:30-09:00 *Swedish AML Steering Group meeting (in Swedish). Only for the steering group*

08:30-09:30 Annual meeting of Swedish AML Group (in Swedish). Chair Martin Höglund, Uppsala

- report of the activities 2018
- plans for 2020-21

09:45-10:00 Coffee

10:00-12:00 SCIENTIFIC PROGRAM I: Relapsed / refractory AML (Chair Martin Höglund, Uppsala)

10:00-10:40 Keynote lecture: Novel approaches to relapsed and refractory AML
(Sabine Kayser, Heidelberg, DE)

10:40-10:50 Brief Discussion

10:50-11:10 AXL inhibition with bemcentinib (Bjørn Tore Gjertsen, Bergen)

11:10-11:15 Brief Discussion

11:15-11:35 Therapy for relapse post allogeneic stem cell transplantation (Yngvar Fløisand, Oslo)

11:35-11:40 Brief Discussion

11:40-12:00 Efficacy and toxicity of venetoclax in clinical routine (Martin Jädersten, Magnus
Tobiasson, Stockholm)

12:00-12:15 Longer Discussion

12:00-13:00 Lunch

13:00-14:30 SCIENTIFIC PROGRAM II: Current clinical trials (Chair Stefan Deneberg, Stockholm)

13:00-13:30 Overview of on-going and upcoming AML-studies (Stefan Deneberg, Stockholm)

13:30-13:50 HOVON studies (HO150 and HO156) (Martin Höglund, Uppsala)

13:50-14:10 Biomarker driven study (Sören Lehmann, Uppsala)

14:10-14:30 HEAT study (Martin Jädersten, Stockholm)

14:30-15:00 Concluding remarks followed by coffee